The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Nanoparticle Albumin–bound Paclitaxel Market Research Report 2025

Global Nanoparticle Albumin–bound Paclitaxel Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1791097

No of Pages : 94

Ask Your Query
Synopsis
Nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division
Global Nanoparticle Albumin–bound Paclitaxel market is projected to reach US$ 3896.4 million in 2029, increasing from US$ 2864 million in 2022, with the CAGR of 4.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanoparticle Albumin–bound Paclitaxel market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Nanoparticle Albumin–bound Paclitaxel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol Myers Squibb
CSPC
Hengrui Medical
Hisun Pharma
Qilu Pharma
Mylan Pharmaceuticals
Apotex
Cipla
Panacea Biotech
Teva
Segment by Type
Patent Medicine
Generic Drug
Segment by Application
Breast Cancer
Non-small Cell Lung Cancer
Pancreatic Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nanoparticle Albumin–bound Paclitaxel report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanoparticle Albumin–bound Paclitaxel Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Patent Medicine
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global Nanoparticle Albumin–bound Paclitaxel Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Non-small Cell Lung Cancer
1.3.4 Pancreatic Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nanoparticle Albumin–bound Paclitaxel Market Perspective (2018-2029)
2.2 Nanoparticle Albumin–bound Paclitaxel Growth Trends by Region
2.2.1 Global Nanoparticle Albumin–bound Paclitaxel Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanoparticle Albumin–bound Paclitaxel Historic Market Size by Region (2018-2023)
2.2.3 Nanoparticle Albumin–bound Paclitaxel Forecasted Market Size by Region (2024-2029)
2.3 Nanoparticle Albumin–bound Paclitaxel Market Dynamics
2.3.1 Nanoparticle Albumin–bound Paclitaxel Industry Trends
2.3.2 Nanoparticle Albumin–bound Paclitaxel Market Drivers
2.3.3 Nanoparticle Albumin–bound Paclitaxel Market Challenges
2.3.4 Nanoparticle Albumin–bound Paclitaxel Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nanoparticle Albumin–bound Paclitaxel Players by Revenue
3.1.1 Global Top Nanoparticle Albumin–bound Paclitaxel Players by Revenue (2018-2023)
3.1.2 Global Nanoparticle Albumin–bound Paclitaxel Revenue Market Share by Players (2018-2023)
3.2 Global Nanoparticle Albumin–bound Paclitaxel Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanoparticle Albumin–bound Paclitaxel Revenue
3.4 Global Nanoparticle Albumin–bound Paclitaxel Market Concentration Ratio
3.4.1 Global Nanoparticle Albumin–bound Paclitaxel Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanoparticle Albumin–bound Paclitaxel Revenue in 2022
3.5 Nanoparticle Albumin–bound Paclitaxel Key Players Head office and Area Served
3.6 Key Players Nanoparticle Albumin–bound Paclitaxel Product Solution and Service
3.7 Date of Enter into Nanoparticle Albumin–bound Paclitaxel Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nanoparticle Albumin–bound Paclitaxel Breakdown Data by Type
4.1 Global Nanoparticle Albumin–bound Paclitaxel Historic Market Size by Type (2018-2023)
4.2 Global Nanoparticle Albumin–bound Paclitaxel Forecasted Market Size by Type (2024-2029)
5 Nanoparticle Albumin–bound Paclitaxel Breakdown Data by Application
5.1 Global Nanoparticle Albumin–bound Paclitaxel Historic Market Size by Application (2018-2023)
5.2 Global Nanoparticle Albumin–bound Paclitaxel Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nanoparticle Albumin–bound Paclitaxel Market Size (2018-2029)
6.2 North America Nanoparticle Albumin–bound Paclitaxel Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2018-2023)
6.4 North America Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nanoparticle Albumin–bound Paclitaxel Market Size (2018-2029)
7.2 Europe Nanoparticle Albumin–bound Paclitaxel Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2018-2023)
7.4 Europe Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nanoparticle Albumin–bound Paclitaxel Market Size (2018-2029)
8.2 Asia-Pacific Nanoparticle Albumin–bound Paclitaxel Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanoparticle Albumin–bound Paclitaxel Market Size by Region (2018-2023)
8.4 Asia-Pacific Nanoparticle Albumin–bound Paclitaxel Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nanoparticle Albumin–bound Paclitaxel Market Size (2018-2029)
9.2 Latin America Nanoparticle Albumin–bound Paclitaxel Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2018-2023)
9.4 Latin America Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nanoparticle Albumin–bound Paclitaxel Market Size (2018-2029)
10.2 Middle East & Africa Nanoparticle Albumin–bound Paclitaxel Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2018-2023)
10.4 Middle East & Africa Nanoparticle Albumin–bound Paclitaxel Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Nanoparticle Albumin–bound Paclitaxel Introduction
11.1.4 Bristol Myers Squibb Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.1.5 Bristol Myers Squibb Recent Development
11.2 CSPC
11.2.1 CSPC Company Detail
11.2.2 CSPC Business Overview
11.2.3 CSPC Nanoparticle Albumin–bound Paclitaxel Introduction
11.2.4 CSPC Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.2.5 CSPC Recent Development
11.3 Hengrui Medical
11.3.1 Hengrui Medical Company Detail
11.3.2 Hengrui Medical Business Overview
11.3.3 Hengrui Medical Nanoparticle Albumin–bound Paclitaxel Introduction
11.3.4 Hengrui Medical Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.3.5 Hengrui Medical Recent Development
11.4 Hisun Pharma
11.4.1 Hisun Pharma Company Detail
11.4.2 Hisun Pharma Business Overview
11.4.3 Hisun Pharma Nanoparticle Albumin–bound Paclitaxel Introduction
11.4.4 Hisun Pharma Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.4.5 Hisun Pharma Recent Development
11.5 Qilu Pharma
11.5.1 Qilu Pharma Company Detail
11.5.2 Qilu Pharma Business Overview
11.5.3 Qilu Pharma Nanoparticle Albumin–bound Paclitaxel Introduction
11.5.4 Qilu Pharma Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.5.5 Qilu Pharma Recent Development
11.6 Mylan Pharmaceuticals
11.6.1 Mylan Pharmaceuticals Company Detail
11.6.2 Mylan Pharmaceuticals Business Overview
11.6.3 Mylan Pharmaceuticals Nanoparticle Albumin–bound Paclitaxel Introduction
11.6.4 Mylan Pharmaceuticals Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.6.5 Mylan Pharmaceuticals Recent Development
11.7 Apotex
11.7.1 Apotex Company Detail
11.7.2 Apotex Business Overview
11.7.3 Apotex Nanoparticle Albumin–bound Paclitaxel Introduction
11.7.4 Apotex Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.7.5 Apotex Recent Development
11.8 Cipla
11.8.1 Cipla Company Detail
11.8.2 Cipla Business Overview
11.8.3 Cipla Nanoparticle Albumin–bound Paclitaxel Introduction
11.8.4 Cipla Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.8.5 Cipla Recent Development
11.9 Panacea Biotech
11.9.1 Panacea Biotech Company Detail
11.9.2 Panacea Biotech Business Overview
11.9.3 Panacea Biotech Nanoparticle Albumin–bound Paclitaxel Introduction
11.9.4 Panacea Biotech Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.9.5 Panacea Biotech Recent Development
11.10 Teva
11.10.1 Teva Company Detail
11.10.2 Teva Business Overview
11.10.3 Teva Nanoparticle Albumin–bound Paclitaxel Introduction
11.10.4 Teva Revenue in Nanoparticle Albumin–bound Paclitaxel Business (2018-2023)
11.10.5 Teva Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock